Login to Your Account

Celgene's Revlimid NDA Done; Myeloma Data Due This Week

By Randall Osborne

Monday, April 11, 2005
As expected, Celgene Corp. finished its rolling new drug application for Revlimid, asking for the FDA's approval based on Phase II data with the compound for myelodysplastic syndromes (MDS) in transfusion-dependent patients with a 5q-deletion chromosomal abnormality. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription